PI3K-independent mTOR activation promotes lapatinib resistance and IAP expression that can be effectively reversed by mTOR and Hsp90 inhibition

Biomarker-guided sequential targeted therapies to overcome therapy resistance in rapidly evolving highly aggressive mammary tumors

(2014) Ozgur Sahin et al.   CELL RESEARCH

Birinapant (TL32711), a Bivalent SMAC Mimetic, Targets TRAF2-Associated cIAPs, Abrogates TNF-Induced NF- B Activation, and Is Active in Patient-Derived Xenograft Models

(2014) C. A. Benetatos et al.   MOLECULAR CANCER THERAPEUTICS

Tumour heterogeneity and the evolution of polyclonal drug resistance

(2014) Rebecca A. Burrell et al.   Molecular Oncology

The Novel SMAC Mimetic Birinapant Exhibits Potent Activity against Human Melanoma Cells

(2013) C. Krepler et al.   CLINICAL CANCER RESEARCH

Control of apoptosis by the BCL-2 protein family: implications for physiology and therapy

(2013) Peter E. Czabotar et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY

Smac mimetic Birinapant induces apoptosis and enhances TRAIL potency in inflammatory breast cancer cells in an IAP-dependent and TNF-α-independent mechanism

(2012) Jennifer L. Allensworth et al.   BREAST CANCER RESEARCH AND TREATMENT

PI3K independent activation of mTORC1 as a target in lapatinib-resistant ERBB2+ breast cancer cells

(2012) Anna-Maria Jegg et al.   BREAST CANCER RESEARCH AND TREATMENT

Concomitant Targeting of Tumor Cells and Induction of T-cell Response Synergizes to Effectively Inhibit Trastuzumab-Resistant Breast Cancer

(2012) Q. Wang et al.   CANCER RESEARCH

mTOR Signaling in Growth Control and Disease

(2012) Mathieu Laplante et al.   CELL

Hsp90 Molecular Chaperone Inhibitors: Are We There Yet?

(2012) L. Neckers et al.   CLINICAL CANCER RESEARCH

Adverse events associated with mTOR inhibitors

(2012) Nicolas Pallet et al.   Expert Opinion On Drug Safety

Safety and tolerability of AZD8055 in Japanese patients with advanced solid tumors; a dose-finding phase I study

(2012) Hajime Asahina et al.   INVESTIGATIONAL NEW DRUGS

Comprehensive molecular portraits of human breast tumours

(2012) Daniel C. Koboldt et al.   NATURE

PI3K pathway activation results in low efficacy of both trastuzumab and lapatinib

(2011) Leiping Wang et al.   BMC CANCER

Resistance to HER2-directed antibodies and tyrosine kinase inhibitors

(2011) Joan T. Garrett et al.   CANCER BIOLOGY & THERAPY

Multiple Mutations and Bypass Mechanisms Can Contribute to Development of Acquired Resistance to MET Inhibitors

(2011) J. Qi et al.   CANCER RESEARCH

IAPS : More than just inhibitors of apoptosis proteins

(2011) Laurence Dubrez-Daloz et al.   CELL CYCLE

Role of ERK-BIM and STAT3-Survivin Signaling Pathways in ALK Inhibitor-Induced Apoptosis in EML4-ALK-Positive Lung Cancer

(2011) K. Takezawa et al.   CLINICAL CANCER RESEARCH

HSP90 Inhibition Is Effective in Breast Cancer: A Phase II Trial of Tanespimycin (17-AAG) Plus Trastuzumab in Patients with HER2-Positive Metastatic Breast Cancer Progressing on Trastuzumab

(2011) S. Modi et al.   CLINICAL CANCER RESEARCH

Combating trastuzumab resistance by targeting SRC, a common node downstream of multiple resistance pathways

(2011) Siyuan Zhang et al.   NATURE MEDICINE

Treatment of HER2-positive breast cancer: current status and future perspectives

(2011) Carlos L. Arteaga et al.   Nature Reviews Clinical Oncology

MK-2206, an Allosteric Akt Inhibitor, Enhances Antitumor Efficacy by Standard Chemotherapeutic Agents or Molecular Targeted Drugs In vitro and In vivo

(2010) H. Hirai et al.   MOLECULAR CANCER THERAPEUTICS

Mitochondria and cell death: outer membrane permeabilization and beyond

(2010) Stephen W. G. Tait et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY

Novel Mechanism of Lapatinib Resistance in HER2-Positive Breast Tumor Cells: Activation of AXL

(2009) L. Liu et al.   CANCER RESEARCH

Lapatinib Combined With Letrozole Versus Letrozole and Placebo As First-Line Therapy for Postmenopausal Hormone Receptor–Positive Metastatic Breast Cancer

(2009) Stephen Johnston et al.   JOURNAL OF CLINICAL ONCOLOGY

Molecular predictors of response to trastuzumab and lapatinib in breast cancer

(2009) Francisco J. Esteva et al.   Nature Reviews Clinical Oncology

Phosphatidylinositol 3-Kinase Hyperactivation Results in Lapatinib Resistance that Is Reversed by the mTOR/Phosphatidylinositol 3-Kinase Inhibitor NVP-BEZ235

(2008) P. J.A. Eichhorn et al.   CANCER RESEARCH

The Identification of 2-(1H-Indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine (GDC-0941) as a Potent, Selective, Orally Bioavailable Inhibitor of Class I PI3 Kinase for the Treatment of Cancer†

(2008) Adrian J. Folkes et al.   JOURNAL OF MEDICINAL CHEMISTRY

Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity

(2008) S.-M. Maira et al.   MOLECULAR CANCER THERAPEUTICS